Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 +5.26%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
